Натриеви каналопатии и епилепсия (I част)

Beck, V., Hull, J., Isom, L. Beyond Dravet Syndrome: Characterization of a Novel, More Severe SCN1A-Linked Epileptic Encephalopathy. Epilepsy Curr, 2019, 19, 4, 266-268.

Berecki, G., Bryson, A., Terhag, J. et al. SCN1A gain of function in early infantile encephalopathy. Ann Neurol, 2019, 85, 4, 514-525.

Brunklaus, A., Ellis, R., Stewart, H. et al. Homozygous mutations in the SCN1A gene associated with genetic epilepsy with febrile seizures plus and Dravet syndrome in 2 families. Eur J Paediatr Neurol ,2015, 19, 484-8.

Camfield, P., Camfield, C. Febrile seizures and genetic epilepsy with febrile seizures plus (GEFS+). Epileptic Disord, 2015, 17, 2, 124-33.

Carroll, L., Woolf, R., Ibrahim, Y. et al. Mutation screening of SCN2A in schizophrenia and identification of a novel loss-offunction mutation. Psychiatr Genet, 2016, 26, 2, 60-65.

Chiron, C., Marchand, M., Tran, A. et al. Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO study group. Lancet, 2000, 356, 1638–1642.

de Lange, I., Gunning, B., Sonsma, A. et al. Outcomes and comorbidities of SCN1A-related seizure disorders. Epilepsy Behav, 2019, 90, 252-259.

Dravet C. The core Dravet syndrome phenotype. Epilepsia, 2011,Suppl 2, 3-9.

Dressler, A., Trimmel-Schwahofer, P., Reithofer, E. et al. Efficacy and tolerability of the ketogenic diet in Dravet syndrome: comparison with various standard antiepileptic drug regimen. Epilepsy Res, 2015, 109, 81-89.

Eckhaus, J., Lawrence, K., Helbig, I. et al. Genetics of febrile seizure subtypes and syndromes: a twin study. Epilepsy Res, 2013, 105, 1-2.

Escayg, A., Goldin, A. Sodium channel SCN1A and epilepsy: mutations and mechanisms. Epilepsia, 2010, 51, 9, 1650-8.

Fazeli, W., Becker, K., Herkenrath, P. et al. Dominant SCN2A Mutation Causes Familial Episodic Ataxia and Impairment of Speech Development. Neuropediatrics, 2018, 49, 6, 379-384.

Guerrini, R., Dravet, C., Genton, P., Belmonte, A., Kaminska, A., Dulac, O. Lamotrigine and seizure aggravation in severe myoclonic epilepsy. Epilepsia, 1998, 39, 508-512.

Howell, K., McMahon, J., Carvill, G. et al. SCN2A encephalopathy: A major cause of epilepsy of infancy with migrating focal seizures. Neurology, 2015, 15, 85, 11, 958-966.

Huang, Q., Yu, L., Ma, M., Qi, H., Wu, Y. Novel SCN2A mutation in a family associated with juvenile-onset myoclonus: Case report. Medicine (Baltimore), 2019, 98, 8, e14698.

Inoue, Y., Ohtsuka, Y., Oguni, H. et al. Stiripentol open study in Japanese patients with Dravet syndrome. Epilepsia, 2009, 50, 2362-2368.

Inoue, Y., Ohtsuka, Y., Group STPS. Long-term safety and efficacy of stiripentol for the treatment of Dravet syndrome: a multicenter, open-label study in Japan. Epilepsy Res, 2015, 113, 90-97.

Kim, JM. Ketogenic diet: old treatment, new beginning. Clin Neurophysiol Pract, 2017, 2, 161-162

Kivity, S., Oliver, K., Afawi ,Z. et al. SCN1A clinical spectrum includes the self-limited focal epilepsies of childhood. Epilepsy Res, 2017, 131, 9-14.

Liu, F., Peng J, Zhu C, et al. Efficacy of the ketogenic diet in Chinese children with Dravet syndrome: a focus on neuropsychological development. Epilepsy Behav. 2019, 92, 98-102.

Marini, C., Harkin, L., Wallace, R. et al. Childhood absence epilepsy and febrile seizures: a family with a GABA(A) receptor mutation. Brain, 2003, 126, 230-40.

Mei, D., Cetica, V., Marini, C., Guerrini, R. Dravet syndrome as part of the clinical and genetic spectrum of sodium channel epilepsies and encephalopathies. Epilepsia, 2019, 60, Suppl 3, S2-S7.

Melikishvili, G., Dulac, O., Gataullina, S. Neonatal SCN2A encephalopathy: A peculiar recognizable electroclinical sequence. Epilepsy Behav, 2020, 111, 107187.

Myers, K., Lightfoot, P,. Patil, S., Cross, J., Scheffer, I. Stiripentol efficacy and safety in Dravet syndrome: a 12-year obser - vational study. Dev Med Child Neurol, 2018, 60, 574-8.

Myers, K., Scheffer, I., Berkovic, S, ILAE Genetics Commission. Genetic literacy series: genetic epilepsy with febrile seizures plus. Epileptic Disord, 2018, 20, 4, 232-238.

Nabbout, R., Copioli, C., Chipaux, M. et al. Ketogenic diet also benefits Dravet syndrome patients receiving stiripentol: a prospective pilot study. Epilepsia, 2011, 52, 54-57.

Nabbout, R., Auvin, S., Zuberi, S. et al. Fenfluramine for Treatment-Resistant Seizures in Patients With Dravet Syndrome Receiving Stiripentol-Inclusive Regimens - A Randomized Clinical Trial. JAMA Neurol, 2020, 77, 3, 300-308.

Reynolds, C., King, M., Gorman, K. The phenotypic spectrum of SCN2A-related epilepsy. Eur J Paediatr Neurol, 2020, 24, 117-122.

Schwarz, N., Bast, T., Gaily, E. et al. Clinical and genetic spectrum of SCN2A-associated episodic ataxia. Eur J Paediatr Neurol, 2019, 23, 3, 438-447.

Scheffer, I., Berkovic, S.. Generalized epilepsy with febrile seizures+: a genetic disorder with heterogeneous clinical phenotypes. Brain, 1997, 120, 479-90.

Scheffer, I., Harkin, L., Grinton, B. et al. Temporal lobe epilepsy and GEFS+ phenotypes associated with SCN1B mutations. Brain, 2007, 130, 100-9.

Scheffer, I., Nabbout, R. SCN1A-related phenotypes: Epilepsy and beyond. Epilepsia, 2019, Suppl 3, 17-24.

Shi, X., Yasumoto, S., Kurahashi, H., Nakagawa, E., Fukasawa, T., Uchiya, S., Hirose, S. Clinical spectrum of SCN2A mutations. Brain Dev, 2012, 34, 7, 541-545.

Singh, R., Andermann, E., Whitehouse, W. et al. Severe myoclonic epilepsy of infancy: extended spectrum of GEFS+? Epilepsia, 2001, 42, 837-844.

Spagnoli, C., Frattini, D., Rizzi, S., Salerno, G., Fusco, C. Early infantile SCN1A epileptic encephalopathy: Expanding the genotype- phenotype correlations. Seizure, 2019, 65, 62-64.

Striano P, Coppola A, Pezzella M, et al. An open-label trial oflevetiracetam in severe myoclonic epilepsy of infancy. Neurology, 2007, 69, 250-4 .

Sugawara, T., Tsurubuchi, Y., Agarwala, K. et al. A missense mutation of the Na+ channel alpha II subunit gene Na(v)1.2 in a patient with febrile and afebrile seizures causes channel dysfunction. Proc Natl Acad Sci USA, 2001, 22, 11, 6384-6389.

Wallace, R., Hodgson, B., Grinton, B. et al. Sodium channel alpha1-subunit mutations in severe myoclonic epilepsy of infancy and infantile spasms. Neurology, 2003, 61, 765-769.

Wheless, J., Fulton, S., Mudigoudar, B. Dravet Syndrome: A Review of Current Management. Pediatr Neurol, 2020, 107, 28-40.

Wirrell, E., Nabbout, R. Recent Advances in the Drug Treatment of Dravet Syndrome. CNS Drugs, 2019, 33, 9, 867-881.

Wolff, M., Brunklaus, A., Zuberi, S. Phenotypic spectrum and genetics of SCN2A-related disorders, treatment options, and outcomes in epilepsy and beyond. Epilepsia, 2019, 60, Suppl 3, S59-S67.

Yokoi, T., Enomoto, Y., Tsurusaki, Y., Naruto, T., Kurosawa, K. Nonsyndromic intellectual disability with novel heterozygous SCN2A mutation and epilepsy. Human Genome Variation, 2018, 5, 20, 1-3.

Yan N, Xin-Hua W, Lin-Mei Z, et al. Prospective study of the efficacy of a ketogenic diet in 20 patients with Dravet syndrome. Seizure, 2018, 60, 144-8.

Zhang, Y., Burgess, R., Malone, J. et al. Genetic epilepsy with febrile seizures plus: Refining the spectrum. Neurology, 2017, 89, 12, 1210-1219.